VNDA

Biotechnology Uncategorized VNDA

Vanda granted public hearing to review FDA denying Hetlioz for jet lag

Mar 3, 2026

Biotechnology Edmund Ingham Uncategorized VNDA

Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn’t Feel Dizzy

Feb 23, 2026

Biotechnology Uncategorized VNDA

Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia

Feb 21, 2026

Biotechnology Petri Dish Reports Uncategorized VNDA

Vanda Pharma: High Risk, Heavily Discounted – Stock Ahead Of PDUFA This Week

Feb 19, 2026

vanda-surges-on-fda-approval-of-lilly-partnered-motion-sickness-therapy

Biotechnology LLY Uncategorized VNDA

Vanda surges on FDA approval of Lilly-partnered motion sickness therapy

Dec 31, 2025

On the Move Comments (4) Grandbrothers/iStock Editorial via Getty Images Vanda Pharmaceuticals (VNDA) added ~21%...